$ECC

Eagle Point Credit Co (ECC): Management’s unaudited estimate of the range of the net asset value per common share as of September 30, 2026 was between $4.12 and $4.22

Eagle Point Credit Co (ECC) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. Management’s unaudited estimate of the range of the net asset value per common share as of September 30, 2026 was between $4.12 and $4.22. In addition, for the quarter ended September 30, 2026, management’s unaudited estimate of the range of the Company's

Original reporting
Published Oct 14, 2026, 12:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 14, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ECC
Neutral
medium confidence
Mentioned
$ECC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ECCNeutralLow
01

Why it matters

The filing provides the first public estimate of the fund’s valuation for the quarter, offering a data point for price assessment.

02

Market read

Primary disclosure of NAV guidance for a small‑cap credit fund; modest trading relevance.

03

What to watch

Potential impact of upcoming credit market conditions on the fund’s asset performance.

Relevance 5/10Novelty 5/10Timing: today

Background

Eagle Point Credit Co filed an 8‑K filing disclosing its unaudited net asset value per share and net investment income for Q3 2026.

Company-level read

Ticker impact

$ECCNeutralMedium confidence
Context

SEC 8‑K reports management’s unaudited NAV estimate of $4.12‑$4.22 per share for Q3 2026.

Expected impact

possible modest upside if market views the NAV as higher than prior expectations, or pressure if seen as lower.

Evidence & confidence

NAV guidance is new information but the absolute dollar range is modest for a small‑cap BDC, limiting material impact.

Market effects

Limited; may slightly affect other BDCs as investors compare NAV guidance.

None

None

Counterpoint

Investors could view the NAV range as a buying opportunity if they expect higher future earnings.

Key entities

  • Eagle Point Credit Co

    Closed‑end credit fund listed on NYSE under ticker ECC.

Related articles

$BBAIHigh

Cantor Fitzgerald cuts BigBear.ai stock price target on execution concerns

Cantor Fitzgerald reduced its price target on BigBear.ai (BBAI) to $3.00 from $4.00, citing execution concerns. The stock is down 65% over the past year. BigBear.ai reported Q3 revenue of $43.6M, up 31.5% YoY, but adjusted EBITDA was negative $9.1M. The company raised its fiscal 2026 revenue guidance to $150M-$165M. Analysts do not expect profitability this year, with EPS forecast at -$0.03 for FY2026.

$MRNAHigh

Why is Moderna stock rebounding today?

Moderna (MRNA) stock rose 3.1% to $214.41 after positive Phase 3 trial data for its cancer vaccine was presented, showing a 42% reduction in melanoma recurrence risk. Piper Sandler raised its price target to $230, countering a prior downgrade. Analysts remain divided, with a consensus 'Hold' rating. The stock had fallen 18% the prior week. Earnings are due November 6.

$GMABHigh

Genmab A/S: Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Genmab (GMAB) reported positive Phase 3 trial results for petosemtamab in combination with pembrolizumab, showing a 50% reduction in death risk for PD-L1+ head and neck cancer patients. The trial met both primary endpoints, and the company plans to engage regulators and present full results. Petosemtamab is also being evaluated in other Phase 3 trials for different cancers.